Credit: Getty Images
HealthDay News â Forty-five percent of adults hospitalized for COVID-19 experienced functional decline impacting survival, according to a study published online April 30 in
PM&R.
Alecia K. Daunter, M.D., from the University of Michigan Health System in Ann Arbor, and colleagues examined the prevalence of functional decline and related rehabilitation needs at hospital discharge for 288 hospitalized adults with laboratory-confirmed COVID-19, with admission dates between March 4 and May 1, 2020.
The researchers found that almost 20 percent of COVID-19 survivors were discharged to a location that was not their home. Overall, functional decline impacting discharge was experienced by 45 percent of the survivors. Of the survivors who showed functional change during hospitalization, 80.6 percent were referred for additional therapy at discharge. Of these, at discharge, at least 67.6 percent required durable medical equipment (no clear documentation in 12 cases)
May 24, 2021
Michigan Medicine to lift some visitor restrictions this week as COVID-19 infection rates decline Changes will allow one adult visitor for adult patients beginning Wednesday
ANN ARBOR – With infection rates and hospitalizations for COVID-19 dropping, Michigan Medicine will lift some visitor restrictions for adult patients that had been required during the most recent surge of patients.
After closely monitoring dropping infection rates, Michigan Medicine leaders have determined that some visitor restrictions can be changed.
On Wednesday at 7 a.m., policies for adult patients will change. One single visitor will be allowed each day between 9 a.m. and 9 p.m. for adult patients in the hospital. Visitors are limited to one person, not multiple visitors in a day. There are exceptions for longer hours for those with developmental delays and significant cognitive impairments.
May 17, 2021
A de-escalation antiplatelet strategy of switching from the more-potent ticagrelor (Brilinta; AstraZeneca) to clopidogrel at 1 month after PCI for acute MI is superior to continuing on ticagrelor and aspirin in terms of net clinical benefit, according to the TALOS-AMI trial.
“This study was conducted only in South Korea. However, although the prevalence of the CYP2C19 loss-of-function allele is significantly higher in Koreans than in other ethnic groups, this study showed the clinical safety of switching in this population, suggesting the potential of applying this de-escalation strategy to other ethnic groups,” said Kiyuk Chang, MD, PhD (The Catholic University of Korea, Seoul, Republic of Korea), who presented the findings in a late-breaking clinical trial session yesterday at the American College of Cardiology 2021 Scientific Session.
Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
Market Leader in Digestive Health Enzymedica Expands New Scientific Advisory Board, Adding Prominent Gastroenterologist and Integrative Medicine Expert Dr. Marvin Singh
Share Article
Dr. Singh, who is board-certified in gastroenterology and internal medicine as well as a Diplomate of the American Board of Integrative Medicine, will lend his deep expertise to the Enzymedica board. He joins its team of natural health and wellness experts who will support the company’s innovative education, research and product development efforts.
Dr. Singh is double-board certified in gastroenterology and internal medicine and is a Diplomate of the American Board of Integrative Medicine.
“Our vision and Dr. Singh’s philosophy are well-aligned – to help individuals feel well, obtain their health goals and take control of their lives,” said Scott Sensenbrenner, President & CEO of Enzymedica.